Laromestrocel is under clinical development by Longeveron and currently in Phase II for Hypoplastic Left Heart Syndrome. According to GlobalData, Phase II drugs for Hypoplastic Left Heart Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Laromestrocel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Laromestrocel overview
Lomecel-B is under development for the treatment of hypoplastic left heart syndrome in infants,osteoarthritis and Alzheimer's disease. It is administered through intramyocardial and intravenous route. The drug candidate comprises of allogeneic human mesenchymal stem cells (hMSC). It acts by inhibiting Matrix Metalloproteinase 14 (MMP14).
It was under development for the treatment of ageing frailty, acute respiratory distress syndrome caused by coronavirus disease 2019 (COVID-19), unspecified influenza virus infections.
Longeveron overview
Longeveron is a clinical-stage biotechnology company that focuses on developing cellular therapies for aging-related and life-threatening conditions. The company’s main activities carry out research and development of regenerative medicine aimed at improving healthspan. Its product is Lomecel-B, derived from culture-expanded medicinal signaling cells sourced from bone marrow. Longeveron’s products are primarily targeted at patients with conditions such as hypoplastic left heart syndrome, Alzheimer’s disease, and aging frailty. It collaborates with partners like the Alzheimer’s Association to advance clinical research. The company operates through manufacturing plants in the US. Longeveron is headquartered in Miami, Florida, the US.
For a complete picture of Laromestrocel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
